Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

NCT02937701 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

558

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

BIOLOGICAL: ABP 710
BIOLOGICAL: Infliximab

Sponsor

Amgen